全球髓母细胞瘤药物市场 – 行业趋势和 2029 年预测

髓母细胞瘤药物市场分析和规模

预测期内，髓母细胞瘤药物市场预计将出现显着增长。脑肿瘤发病率的不断上升预计将在预测期内促进市场的增长。全球脑肿瘤和其他类型癌症发病率的增加将推动全球髓母细胞瘤药物市场的发展。但是，脑肿瘤发生的确切原因和癌症的晚期症状可能会阻碍全球髓母细胞瘤药物市场的发展。COVID-19 也对市场增长产生了重大影响。

Data Bridge Market Research 分析了 2022-2029 年预测期内全球髓母细胞瘤药物市场的增长率。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

髓母细胞瘤药物市场范围和细分

Market Definition

Medulloblastoma is a type of brain tumor that occurs in the lower back part of the brain, called the cerebellum. The cerebellum helps in muscle coordination, balance and movement. Medulloblastoma is an embryonal tumor that initiates in the embryonic cells in the brain. The patient suffers from headaches, nausea, tiredness, dizziness, double vision, vomiting, and poor coordination; this condition also develops unsteady walk and pressure build up in the brain. The tumor rarely spreads to other areas of the body.

Global Medulloblastoma Drug Market Dynamics

Drivers

• Growing Surgeries and Reimbursement Policies

The presence of reimbursement policies that boost healthcare professionals to maintain quality infrastructure is estimated to increase the demand for surgery in this market. Thus, more and more success rate of surgeries and reimbursement policies is surely expected to increase the market growth. In addition, the number of surgical procedures for treating glioma in emerging economies, including China and India, is growing. Governments of China and India have improved their healthcare spend, which in turn is augmenting the admission of patients in hospitals.

• Rising Demand for Drugs

There has been several drugs that are helping in increasing the growth of the market. Temozolomide is a drug that is anticipated to treat some types of brain cancer such as  glioblastoma multiforme, anaplastic astrocytoma in individuals who have had tumours return or who have recently been diagnosed with tumours. Thus, it boosts the growth of the market.

Opportunities

• Increased Cases of Brain Tumor

According to the National Brain Tumor Society, about 700,000 people in the U.S. will have primary brain tumor in 2019 and around 86,000 more will be diagnosed. The growing number of patients with neurological disorders, including brain tumor, is leading to a rise in the demand for the drugs used in their treatment.

• Rising Healthcare Awareness

Health awareness amongst the population are rising, resulting in the prediction of drugs to boost market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing in launching drugs that benefit the market. This creates more opportunities in the market.

Restraints/Challenges

• Increase in Demand of Targeted Therapy

The rising demand for targeted therapy is somewhat hampering the market's growth. Growing use of targeted therapies is acting as a restraint on the medulloblastoma drug market. For instance, Everolimus is a targeted therapy that blocks cancer cells from growing and spreading. Likewise, Bevacizumab prevents the regeneration of cancer cells, unlike chemical drugs that cannot prevent regeneration. This increasing popularity of targeted therapies is projected to affect the sales of conventional chemical Brain tumor drugs, thus limiting the growth of the market during the forecast period.

• Nanotechnology Restricts Sale of Drugs

Market players in the medulloblastoma drug market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a decline in dosage of the drugs, improved shelf life and decreased toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in treating medulloblastoma.

This global medulloblastoma drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global medulloblastoma drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Medulloblastoma Drug Market

COVID-19 has had a negative impact on the global medulloblastoma drug market. Numerous ICU facilities, such as ventilators, personal protective equipment, and medical staff, were redirected to COVID-19 cases, stimulating the suspension of surgical neuro-oncology services during the COVID-19 pandemic. Instability in the provision of adequate medical care to critically-ill cancer patients was observed during the pandemic. Furthermore, medulloblastoma patients seem to be vulnerable to the COVID-19 infection, which resulted in the postponement of treatments and surgeries. Thus, the market was greatly impacted by the global medulloblastoma drug market.

Global Medulloblastoma Drug Market Scope

全球髓母细胞瘤药物市场根据药物、给药途径、分销渠道和最终用户进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

药物

• 化疗
• 糖皮质激素
• 渗透性利尿剂
•  其他的

给药途径

• 口服
• 肠外
• 其他的

最终用户

• 医院
• 家庭护理
• 专业中心
• 其他的

分销渠道

• 医院药房
• 网上药店
• 零售药店

髓母细胞瘤药物市场区域分析/见解

对全球髓母细胞瘤药物市场进行了分析，并按药物、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。

全球髓母细胞瘤药物市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于拥有该产品的关键制造基地、高水平的研发、医疗保健支出和熟练的专业人员，北美预计将拥有最高的市场增长。

由于政府宣传活动的加强和仿制药数量的增加，亚太地区在市场中占据主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球髓母细胞瘤药物市场份额分析

全球髓母细胞瘤药物市场概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用优势。以上提供的数据点仅与公司对全球髓母细胞瘤药物市场的关注有关。

全球髓母细胞瘤药物市场的主要参与者包括：

• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 拜耳公司（德国）
• 默克公司（美国）
• Abbvie, Inc（美国）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• 雅培（美国）
• Bausch Health Companies Inc.（加拿大）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• Stemline Therapeutics, Inc（美国）
• 小野制药株式会社（日本）
• KINTARA THERAPEUTICS, INC（美国）
• VBI Vaccines Inc（美国）

SKU-55300